Defining post-acute COVID-19 syndrome (PACS) by an epigenetic biosignature in peripheral blood mononuclear cellsShow others and affiliations
2022 (English)Manuscript (preprint) (Other academic)
Abstract [en]
Post-Acute COVID-19 Syndrome (PACS) has been defined as symptoms persisting after clearance of a COVID-19 infection. We have previously demonstrated that alterations in DNA methylation (DNAm) status persists in individuals who recovered from a COVID-19 infection, but it is currently unknown if PACS is associated with epigenetic changes. We compared DNAm patterns in patients with PACS with those in controls and in healthy COVID-19 convalescents and found a unique DNAm signature in PACS patients. This signature unravelled modified pathways that regulate angiotensin II and muscarinic receptor signalling and protein-protein interaction networks that have bearings on vesicle formation and mitochondrial function.
Place, publisher, year, edition, pages
2022.
Keywords [en]
Post-Acute COVID-19 Syndrome, PACS, COVID-19, SARS-CoV-2, PBMC, epigenetics, DNA methylation, biosignature
National Category
Cell and Molecular Biology
Identifiers
URN: urn:nbn:se:liu:diva-189613DOI: 10.21203/rs.3.rs-1816305/v1OAI: oai:DiVA.org:liu-189613DiVA, id: diva2:1707060
Note
This preprint is under Review at Clinical Epigenetics.
2022-10-282022-10-282023-02-08Bibliographically approved